Initial Announcement Back to the Grants Dashboard
Notice of Funding Opportunity (NOFO)
NOFO Number: TI-16-014
Posted on Grants.gov: Tuesday, March 29, 2016
Application Due Date: Tuesday, May 31, 2016
Catalog of Federal Domestic Assistance (CFDA) Number: 93.243
Intergovernmental Review (E.O. 12372): Applicants must comply with E.O. 12372 if their state(s) participates. Review process recommendations from the State Single Point of Contact (SPOC) are due no later than 60 days after application deadline.
Public Health System Impact Statement (PHSIS) / Single State Agency Coordination: Applicants must send the PHSIS to appropriate State and local health agencies by application deadline. Comments from Single State Agency are due no later than 60 days after application deadline.
The purpose of this program is to expand/enhance access to medication-assisted treatment (MAT) services for persons with opioid use disorder seeking or receiving MAT. This program targets states identified with having the highest rates of primary treatment admissions for heroin and opioids per capita, and prioritizes those states with the most dramatic increases for heroin and opioids, based on SAMHSA’s Treatment Episode Data Set (TEDS): 2007 - 2013. The desired outcomes include: 1) an increase in the number of admissions for MAT; 2) an increase in the number of clients receiving integrated care/treatment; 3) a decrease in illicit opioid drug use at 6-month follow-up; and 4) a decrease in the use of prescription opioids in a non-prescribed manner at 6-month follow-up.
For the purpose of this FOA, integrated care/treatment is defined as the organized delivery and/or coordination of medical (including the use of Food and Drug Administration (FDA)-approved drugs [buprenorphine, methadone, naltrexone] for addiction), behavioral, social, peer, and other recovery support services provided to individual patients who have multiple healthcare needs in order to produce better overall health outcomes. MAT is defined as the use of FDA-approved opioid agonist medications (e.g., methadone, buprenorphine products, including buprenorphine/naloxone combination formulations and buprenorphine mono-product formulations) for the maintenance treatment of opioid use disorder and opioid antagonist medication (e.g., naltrexone products, including extended-release and oral formulations) in combination with behavioral therapies to prevent relapse to opioid use. MAT includes screening, assessment (which includes determination of severity of opioid use disorder, including presence of physical dependence and appropriateness for MAT), and case management. MAT is to be provided in combination with comprehensive substance use disorder treatment, including but not limited to: counseling, behavioral therapies, and, when needed, pharmacotherapy for co-occurring alcohol use disorder. MAT is to be provided in a clinically driven, person-centered, and individualized setting.
This program addresses SAMHSA’s Strategic Initiative on Health Care and Health Systems Integration. For more information on SAMHSA’s six strategic initiatives, you can visit /about-us/strategic-initiatives. The MAT-PDOA program seeks to address behavioral health disparities among racial, ethnic, sexual, and gender identity minority populations by encouraging the implementation of strategies to decrease the differences in access, service use, and outcomes among the racial and ethnic minority populations served. (See PART II: Appendix G – Addressing Behavioral Health Disparities.)
The MAT-PDOA program is one of SAMHSA’s services grant programs. SAMHSA intends that its services grants result in the delivery of services as soon as possible after award. Service delivery should begin by the 4th month of the project at the latest.
Eligibility is limited to 28 states identified with having the highest rates of primary treatment admissions for heroin and opioids per capita, and prioritizes those states with the most dramatic increases for heroin and opioids, based on SAMHSA’s Treatment Episode Data Set (TEDS): 2007 – 2013, (see Appendix V for a list of eligible states). The application must be submitted by the Single State Agency (SSA) for Substance Abuse within the state. Eligibility has been limited to these states because an analysis of TEDS data demonstrates that they represent the highest rates of primary treatment admissions with heroin and opiates per capita. In addition, SAMHSA has identified 11 of these states (see Appendix VI) that have demonstrated a dramatic increase of 40 percent or more in admissions for the treatment of opiates and heroin in recent years and will be given priority for funding. This approach is consistent with the language used to describe the program in the FY 2016 Omnibus language. FY 2015 MAT-PDOA grantees funded under announcement TI-15-007 are not eligible to apply for this program.
Funding Mechanism: Grant
Anticipated Total Available Funding: $11,000,000
Anticipated Number of Awards: Up to 11 awards
Anticipated Award Amount: Up to $1 million per year
Length of Project: Up to three years
Cost Sharing/Match Required?: No
Proposed budgets cannot exceed $1,000,000 in total costs (direct and indirect) in any year of the proposed project. Annual continuation awards will depend on the availability of funds, grantee progress in meeting project goals and objectives, timely submission of required data and reports, and compliance with all terms and conditions of award.
Sherrye C. McManus, Ph.D.
Senior Public Health Advisor
Division of Services Improvement, Center for Substance Abuse Treatment
Substance Abuse and Mental Health Services Administration
Grants Management and Budget Issues
Office of Financial Resources, Division of Grants Management
Substance Abuse and Mental Health Services Administration